Journal Mobile Options
Table of Contents
Vol. 42, No. 2, 2009
Issue release date: September 2009
Section title: Original Paper
Ophthalmic Res 2009;42:99–105
(DOI:10.1159/000225963)

Systematic Review of Intraocular Pressure-Lowering Effects of Adjunctive Medications Added to Latanoprost

Cheng J.-W. · Li Y. · Wei R.-L.
Department of Ophthalmology, Shanghai Changzheng Hospital, Second Military Medical University, Shanghai, China

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restriction apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Automatic perpetual access to all articles of the subscribed year(s)
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: 9/8/2008
Accepted: 11/15/2008
Published online: 6/23/2009

Number of Print Pages: 7
Number of Figures: 1
Number of Tables: 4

ISSN: 0030-3747 (Print)
eISSN: 1423-0259 (Online)

For additional information: http://www.karger.com/ORE

Abstract

Objective: To evaluate the intraocular pressure (IOP)-lowering effects of adjunctive medications when added to 0.005% latanoprost taken once daily. Methods: Pertinent publications were identified through systematic searches of PubMed, Embase, and the Cochrane Controlled Trials Register. Randomized clinical trials with over 85% of patients presenting with primary open-angle glaucoma or ocular hypertension who were treated with the combination treatment of latanoprost were selected. The pooled additional IOP-lowering effects at 1–3 months after a run-in phase of at least 2 weeks on 0.005% latanoprost once daily were calculated using the random effects model. Results: Nine randomized clinical trials were included. The mean pooled IOP reductions were 3.3 mm Hg (95% CI: 2.1–4.5) at trough and 4.4 mm Hg (95% CI: 3.4–5.4) at peak when adding 0.5% timolol once daily, 2.6 mm Hg (95% CI: 1.9–3.3) at trough and 3.8 mm Hg (95% CI: 2.5–5.2) at peak when adding 0.1/0.15% brimonidine twice daily, 2.6 mm Hg (95% CI: 1.7–3.4) at trough and 3.1 mm Hg (95% CI: 2.6–3.6) at peak when adding 2% dorzolamide twice daily, 2.4 mm Hg (95% CI: 2.0 –2.8) at trough and 2.7 mm Hg (95% CI: 2.2–3.2) at peak when adding 0.5% timolol twice daily, and 2.8 mm Hg (95% CI: 1.5–4.1) at trough and 1.8 mm Hg (95% CI: 1.2–2.3) at peak when adding 1% brinzolamide twice daily. Conclusions: The addition of brimonidine, dorzolamide, timolol, or brinzolamide can further lower IOP in eyes being treated with latanoprost. Timolol 0.5% once daily might be the most effective adjunctive medication.


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: 9/8/2008
Accepted: 11/15/2008
Published online: 6/23/2009

Number of Print Pages: 7
Number of Figures: 1
Number of Tables: 4

ISSN: 0030-3747 (Print)
eISSN: 1423-0259 (Online)

For additional information: http://www.karger.com/ORE


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Alward WL: Medical management of glaucoma. N Engl J Med 1998;339:1298–1307.
  2. AGIS Investigators: The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000;130:429–440.
  3. Hurvitz LM, Kaufman PL, Robin AL, Weinreb RN, Crawford K, Shaw B: New developments in the drug treatment of glaucoma. Drugs 1991;41:514–532.
  4. Resul B, Stjernschantz J, No K, Liljebris C, Selén G, Astin M, Karlsson M, Bito LZ: Phenyl-substituted prostaglandins: potent and selective antiglaucoma agents. J Med Chem 1993;36:243–248.
  5. Alm A: Prostaglandin derivates as ocular hypotensive agents. Prog Retin Eye Res 1998;17:291–312.
  6. Alexander CL, Miller SJ, Abel SR: Prostaglandin analog treatment of glaucoma and ocular hypertension. Ann Pharmacother 2002;36:504–511.
  7. Zhang WY, Po AL, Dua HS, Azuara-Blanco A: Meta-analysis of randomised controlled trials comparing latanoprost with timolol in the treatment of patients with open angle glaucoma or ocular hypertension. Br J Ophthalmol 2001;85:983–990.
  8. Netland PA, Landry T, Sullivan EK, Andrew R, Silver L, Weiner A, Mallick S, Dickerson J, Bergamini MV, Robertson SM, Davis AA; Travoprost Study Group: Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001;132:472–484.
  9. Noecker RS, Dirks MS, Choplin NT, Bernstein P, Batoosingh AL, Whitcup SM; Bimatoprost/Latanoprost Study Group: A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol 2003;135:55–63.
  10. Choplin N, Bernstein P, Batoosingh AL, Whitcup SM; Bimatoprost/Latanoprost Study Group: A randomized, investigator-masked comparison of diurnal responder rates with bimatoprost and latanoprost in the lowering of intraocular pressure. Surv Ophthalmol 2004;49:S19–S25.
  11. van der Valk R, Webers CA, Schouten JS, Zeegers MP, Hendrikse F, Prins MH: Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology 2005;112:1177–1185.
  12. Verhagen AP, de Vet HC, de Bie RA, Kessels AG, Boers M, Bouter LM, Knipschild PG: The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. J Clin Epidemiol 1998;51:1235–1241.
  13. DerSimonian R, Kacker R: Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials 2007;28:105–114.
  14. Egger M, Davey Smith G, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629–634.
  15. Stewart WC, Day DG, Sharpe ED, Dubiner HB, Holmes KT, Stewart JA: Efficacy and safety of timolol solution once daily vs. timolol gel added to latanoprost. Am J Ophthalmol 1999;128:692–696.
  16. Maruyama K, Shirato S, Haneda M: Evaluation of the additive effect of bunazosin on latanoprost in primary open-angle glaucoma. Jpn J Ophthalmol 2005;49:61–62.
  17. Kobayashi H, Kobayashi K, Okinami S: Efficacy of bunazosin hydrochloride 0.01% as adjunctive therapy of latanoprost or timolol. J Glaucoma 2004;13:73–80.
  18. Konstas AG, Karabatsas CH, Lallos N, Georgiadis N, Kotsimpou A, Stewart JA, Stewart WC: Twenty-four-hour intraocular pressures with brimonidine purite versus dorzolamide added to latanoprost in primary open-angle glaucoma subjects. Ophthalmology 2005;112:603–608.
  19. Haneda M, Shirato S, Maruyama K, Ohno Y: Comparison of the additive effects of nipradilol and carteolol to latanoprost in open-angle glaucoma. Jpn J Ophthalmol 2006;50:33–37.
  20. Maruyama K, Shirato S: Additive effect of dorzolamide or carteolol to latanoprost in primary open-angle glaucoma: a prospective randomized crossover trial. J Glaucoma 2006;15:341–345.
  21. Tamer C, Oksüz H: Circadian intraocular pressure control with dorzolamide versus timolol maleate add-on treatments in primary open-angle glaucoma patients using latanoprost. Ophthalmic Res 2007;39:24–31.
  22. Day DG, Hollander DA: Brimonidine purite 0.1% versus brinzolamide 1% as adjunctive therapy to latanoprost in patients with glaucoma or ocular hypertension. Curr Med Res Opin 2008;24:1435–1442.
  23. Miura K, Ito K, Okawa C, Sugimoto K, Matsunaga K, Uji Y: Comparison of ocular hypotensive effect and safety of brinzolamide and timolol added to latanoprost. J Glaucoma 2008;17:233–237.
  24. Maier PC, Funk J, Schwarzer G, Antes G, Falck-Ytter YT: Treatment of ocular hypertension and open angle glaucoma: meta-analysis of randomised controlled trials. BMJ 2005;331:134–139.
  25. Palmberg P: Evidence-based target pressures: how to choose and achieve them. Int Ophthalmol Clin 2004;44:1–14.
  26. Diestelhorst M, Larsson LI; European Latanoprost Fixed Combination Study Group: A 12 week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients with open angle glaucoma and ocular hypertension. Br J Ophthalmol 2004;88:199–203.
  27. Diestelhorst M, Larsson LI; European-Canadian Latanoprost Fixed Combination Study Group: A 12-week, randomized, double-masked, multicenter study of the fixed combination of latanoprost and timolol in the evening versus the individual components. Ophthalmology 2006;113:70–76.
  28. Olthoff CM, Schouten JS, van de Borne BW, Webers CA: Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review. Ophthalmology 2005;112:953–961.